Harshipraz IT Capsule SR is a combination pharmaceutical formulation containing Esomeprazole 40 mg and Itopride 150 mg, designed for the management of gastrointestinal disorders characterized by acid-related symptoms and impaired motility. Esomeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and providing symptomatic relief in conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcer disease. Itopride, a prokinetic agent, enhances gastrointestinal motility by antagonizing dopamine D2 receptors and inhibiting acetylcholinesterase activity, which facilitates gastric emptying and alleviates symptoms like bloating, nausea, and early satiety commonly associated with functional dyspepsia and gastroparesis. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance and efficacy. Harshipraz IT Capsule SR is indicated for patients requiring combined acid suppression and prokinetic therapy to optimize symptom control and promote mucosal healing. It should be used under medical supervision, considering contraindications such as hypersensitivity to components, and with caution in patients with hepatic impairment. Adverse effects are generally mild and may include headache, diarrhea, or abdominal discomfort. Regular monitoring and adherence to prescribed dosage enhance treatment outcomes.